Echo Therapeutics to Present at Rodman & Renshaw's Annual Global Investment Conference
FRANKLIN, Mass., Nov. 6 /PRNewswire-FirstCall/ --Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE),a diabetes management company developing the Symphony(TM) tCGM System as a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system,announced today that Patrick T. Mooney, M.D, Chairman and Chief Executive Officer, will present at the Rodman & Renshaw's Annual Global Investment Conference on Monday, November 10, 2008, at the New York Palace Hotel. Dr. Mooney's presentation will occur live at 4:30 pm Eastern Time.
About Echo Therapeutics
Echo Therapeutics is focused on transdermal medical devices and specialty pharmaceuticals. Echo's Symphony(TM) tCGM System is in late-stage development as a non-invasive (needle-free), wireless, continuous transdermal continuous glucose monitoring (tCGM) system for patients with Type 1 and Type 2 diabetes and for use in hospital critical care units. Echo's AzoneTS(TM) reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed FDA-approved specialty pharmaceutical products. Echo's Symphony tCGM System consists of its wireless transmission and transdermal biosensor technologies and its Prelude(TM) SkinPrep System, which incorporates leading-edge, needle-free skin permeation control technology. Echo expects its Symphony tCGM System to provide Type 1 and Type 2 diabetes patients and hospital professionals with a reliable, affordable, comfortable-to-wear and easy-to-use, needle-free continuous glucose monitoring device.
Forward-Looking Statements
This press release contains forward-looking information that involves risks and uncertainties, including statements regarding Echo's development plans, objectives, expectations and intentions, including, without limitation, statements regarding its Symphony tCGM System and AzoneTS product development programs. Factors that could adversely affect Echo's business and prospects are described in its filings with the Securities and Exchange Commission. Echo expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Investor Relations Contacts:
Patrick T. Mooney, M.D.
Chairman & CEO
Echo Therapeutics
508-530-0329
